Metastatic Castration-resistant Prostate Cancer Clinical Trials in Durham, North Carolina

6 studies are recruiting for metastatic castration-resistant prostate cancer in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

2. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University Medical Center - Duke Cancer Center, Durham, North Carolina

   Locations

   23 in total

   Run by

   Kyntra Bio

   See if you can join NCT06842498 on ClinicalTrials.gov

3. A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

   The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   15 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06067841 on ClinicalTrials.gov

4. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

   Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Center, Durham, North Carolina

   Locations

   13 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT07103018 on ClinicalTrials.gov

5. Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

   The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   6 in total

   Run by

   Syntrix Biosystems, Inc.

   See if you can join NCT06228053 on ClinicalTrials.gov

6. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

   Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Center, Durham, North Carolina

   Locations

   25 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT04729114 on ClinicalTrials.gov